Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Researchers astatine The University of Texas MD Anderson Cancer Center were capable to eradicate measurable residual illness (MRD) successful B-cell acute lymphoblastic leukemia (ALL) patients, a captious measurement successful improving semipermanent endurance outcomes, by treating them with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.